Top

BMC Cancer

Published in:

01-12-2021 | Metastasis | Research

Identification of TRPV4 as a novel target in invasiveness of colorectal cancer

Authors: Peng Zhang, Jian Xu, Hua Zhang, Xiao-Yu Liu

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Emerging evidence has indicated the critical role of TRPV4 in diverse human cancers. However, the underlying molecular mechanism of TRPV4 in colon cancer invasiveness is still unknown.

Methods

Immunohistochemistry staining was used to analyze the expression of TRPV4 and ZEB1 in clinical tissues; Wound healing and transwell assays were applied to determine the cell invasiveness; Western blot was used to explore the relation between TRPV4 and ZEB1.

Results

Colon cancer cells were transfected with siRNA against TRPV4 or HC067047 (a selective TRPV4 antagonist), TRPV4 full-length plasmid or siRNA against ZEB1, or both, in order to measure cell migration and invasion. And we found that TRPV4 silencing or inhibition exhibited an inhibitory role in colon cancer cell migration and invasion, coupled with compromised EMT process, and suppressed AKT activity. TRPV4 stimulated expression of ZEB1 and consequently contributed to EMT process and invasiveness. It was also revealed that overexpression of TRPV4 and ZEB1 in clinical patients with local metastasis, and positive correlation between TRPV4 and ZEB1.

Conclusions

Our results uncovered the role of TRPV4 in tumor metastasis and highlighted the potential mechanism of TRPV4-ZEB1 axis in indicating EMT.

Available only for authorised users

Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer treatment and survivorship statistics. CA Cancer J Clin. 2019;69(5):363–85. https://doi.org/10.3322/caac.21565.CrossRefPubMed

Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics. CA Cancer J Clin. 2016;66(4):271–89. https://doi.org/10.3322/caac.21349.CrossRefPubMed

van Kalsbeek RJ, van der Pal HJH, Hjorth L, Winther JF, Michel G, Haupt R, et al. The European multistakeholder PanCareFollowUp project: novel, person-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for cancer survivors and caregivers. Eur J Cancer. 2021;153:74–85. https://doi.org/10.1016/j.ejca.2021.05.030.CrossRefPubMed

Gallicchio L, Tonorezos E, de Moor JS, Elena J, Farrell M, Green P, et al. Evidence Gaps in Cancer Survivorship Care: A Report from the 2019 National Cancer Institute Cancer Survivorship Workshop. J Natl Cancer Inst. 2021;113(9):1136–42.CrossRefPubMedPubMedCentral

Miller KD, Fidler-Benaoudia M, Keegan TH, Hipp HS, Jemal A, Siegel RL. Cancer statistics for adolescents and young adults, 2020. CA Cancer J Clin. 2020;70(6):443–59. https://doi.org/10.3322/caac.21637.CrossRefPubMed

Mohile SG, Hurria A, Cohen HJ, Rowland JH, Leach CR, Arora NK, et al. Improving the quality of survivorship for older adults with cancer. Cancer. 2016;122(16):2459–568. https://doi.org/10.1002/cncr.30053.CrossRefPubMed

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. https://doi.org/10.1016/j.cell.2011.02.013.CrossRefPubMed

Tørring ML, Murchie P, Hamilton W, Vedsted P, Esteva M, Winget M, et al. Evidence of advanced stage colorectal cancer with longer diagnostic intervals: a pooled analysis of seven primary care cohorts comprising 11720 patients in five countries. Br J Cancer. 2017;177(6):888–97. https://doi.org/10.1038/bjc.2017.236.CrossRef

Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331(6024):1559–64. https://doi.org/10.1126/science.1203543.CrossRefPubMed

10.

Nilius B, Voets T. The puzzle of TRPV4 channelopathies. EMBO Rep. 2013;14(2):152–63. https://doi.org/10.1038/embor.2012.219.CrossRefPubMedPubMedCentral

11.

Zhang P, Sun C, Li H, Tang C, Kan H, Yang Z, et al. TRPV4 (transient receptor potential Vanilloid 4) mediates endothelium-dependent contractions in the aortas of hypertensive mice. Hypertension. 2018;71(1):134–42. https://doi.org/10.1161/HYPERTENSIONAHA.117.09767.CrossRefPubMed

12.

Lee WH, Choong LY, Jin TH, Mon NN, Chong S, Liew CS, et al. TRPV4 plays a role in breast cancer cell migration via Ca2+−dependent activation of AKT and downregulation of E-cadherin cell cortex protein. Oncogenesis. 2017;6(5):e338. https://doi.org/10.1038/oncsis.2017.39.CrossRefPubMedPubMedCentral

13.

Liu X, Zhang P, Xie C, Sham KWY, Ng SSM, Chen Y, et al. Activation of PTEN by inhibition of TRPV4 suppresses colon cancer development. Cell Death Dis. 2019;10(6):460. https://doi.org/10.1038/s41419-019-1700-4.CrossRefPubMedPubMedCentral

14.

Boesch M, Spizzo G, Seeber A. Concise review: aggressive colorectal cancer: role of epithelial cell adhesion molecule in cancer stem cells and epithelial-to-mesenchymal transition. Stem Cells Transl Med. 2018;7(6):495–501. https://doi.org/10.1002/sctm.17-0289.CrossRefPubMedPubMedCentral

15.

Loboda A, Nebozhyn MV, Watters JW, Buser CA, Shaw PM, Huang PS, et al. EMT is the dominant program in human colon cancer. BMC Med Genet. 2011;4(1):9. https://doi.org/10.1186/1755-8794-4-9.CrossRef

16.

Craene BD, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13(2):97–110. https://doi.org/10.1038/nrc3447.CrossRefPubMed

17.

Zhang P, Liu X, Li H, Chen Z, Yao X, Jin J, et al. TRPC5-induced autophagy promotes drug resistance in breast carcinoma via CaMKKβ/AMPKα/mTOR pathway. Sci Rep. 2017;7(1):3158. https://doi.org/10.1038/s41598-017-03230-w.CrossRefPubMedPubMedCentral

18.

Liu X, Han X, Wan X, He C, Wang Y, Mao A, et al. SPZ1 is critical for chemoresistance and aggressiveness in drug-resistant breast cancer cells. Biochem Pharmacol. 2018;156:43–51. https://doi.org/10.1016/j.bcp.2018.07.046.CrossRefPubMed

19.

Liu X, Wang T, Wang Y, Chen Z, Hua D, Yao X, et al. Orai1 is critical for Notch-driven aggressiveness under hypoxic conditions in triple-negative breast cancers. Biochim Biophys Acta Mol Basis Dis. 2018;1864(4 Pt A):975–86.CrossRefPubMed

20.

Lamprecht S, Kaller M, Schmidt EM, Blaj C, Schiergens TS, Engel J, et al. PBX3 is part of an EMT regulatory network and indicates poor outcome in colorectal Cancer. Clin Cancer Res. 2018;24(8):1974–86. https://doi.org/10.1158/1078-0432.CCR-17-2572.CrossRefPubMed

21.

Lee SY, Jeong EK, Ju MK, Jeon HM, Kim MY, Kim CH, et al. Induction of metastasis, cancer stem cell phenotype, and oncogenic metabolism in cancer cells by ionizing radiation. Mol Cancer. 2017;16(1):10. https://doi.org/10.1186/s12943-016-0577-4.CrossRefPubMedPubMedCentral

22.

Wang Y, Bu F, Royer C, Serres S, Larkin JR, Soto MS, et al. ASPP2 controls epithelial plasticity and inhibits metastasis through beta-catenin-dependent regulation of ZEB1. Nat Cell Biol. 2014;16(11):1092–104. https://doi.org/10.1038/ncb3050.CrossRefPubMed

23.

Xie R, Xu J, Xiao Y, Wu J, Wan H, Tang B, et al. Calcium promotes human gastric cancer via a novel coupling of calcium-sensing receptor and TRPV4 channel. Cancer Res. 2017;77(23):6499–512. https://doi.org/10.1158/0008-5472.CAN-17-0360.CrossRefPubMed

24.

Fang Y, Liu G, Xie C, Qian K, Lei X, Liu Q, et al. Pharmacological inhibition of TRPV4 channel suppresses malignant biological behavior of hepatocellular carcinoma via modulation of ERK signaling pathway. Biomed Pharmacother. 2018;101:910–9. https://doi.org/10.1016/j.biopha.2018.03.014.CrossRefPubMed

25.

Lee WH, Choong LY, Mon NN, Lu S, Lin Q, Pang B, et al. TRPV4 regulates breast cancer cell extravasation, stiffness and actin cortex. Sci Rep. 2016;6(1):27903. https://doi.org/10.1038/srep27903.CrossRefPubMedPubMedCentral

26.

Ou-Yang Q, Li B, Xu M. Liang H.TRPV4 promotes the migration and invasion of glioma cells via AKT/Rac1 signaling. Biochem Biophys Res Commun. 2018;503(2):876–81. https://doi.org/10.1016/j.bbrc.2018.06.090.CrossRefPubMed

27.

Tsanou E, Peschos D, Batistatou A, Charalabopoulos A, Charalabopoulos K. The E-cadherin adhesion molecule and colorectal cancer. A global literature approach. Anticancer Res. 2008;28(6A):3815–26.PubMed

28.

Nakajima S, Doi R, Toyoda E, Tsuji S, Wada M, Koizumi M, et al. N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clin Cancer Res. 2004;10(12 Pt 1):4125–33. https://doi.org/10.1158/1078-0432.CCR-0578-03.CrossRefPubMed

29.

Chaw SY, Majeed AA, Dalley AJ, Chan A, Stein S, Farah CS. Epithelial to mesenchymal transition (EMT) biomarkers--E-cadherin, beta-catenin, APC and Vimentin--in oral squamous cell carcinogenesis and transformation. Oral Oncol. 2012;48(10):997–1006. https://doi.org/10.1016/j.oraloncology.2012.05.011.CrossRefPubMed

30.

Larsen JE, Nathan V, Osborne JK, Farrow RD, Deb D, Sullivan JP, et al. ZEB1 drives epithelial-to-mesenchymal transition in lung cancer. J Clin Invest. 2016;126(9):3219–35. https://doi.org/10.1172/JCI76725.CrossRefPubMedPubMedCentral

31.

Wang Y, Wen M, Kwon Y, Xu Y, Liu Y, Zhang P, et al. CUL4A induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression. Cancer Res. 2014;74(2):520–31. https://doi.org/10.1158/0008-5472.CAN-13-2182.CrossRefPubMed

32.

Spaderna S, Schmalhofer O, Wahlbuhl M, Dimmler A, Bauer K, Sultan A, et al. The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res. 2008;68(2):537–44. https://doi.org/10.1158/0008-5472.CAN-07-5682.CrossRefPubMed

Title: Identification of TRPV4 as a novel target in invasiveness of colorectal cancer
Authors: Peng Zhang
Jian Xu
Hua Zhang
Xiao-Yu Liu
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Metastasis
Colorectal Cancer
Colorectal Cancer
Colon Cancer
Colon Cancer
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08970-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Investigating efficacy of “microbiota modulation of the gut-lung Axis” combined with chemotherapy in patients with advanced NSCLC: study protocol for a multicenter, prospective, double blind, placebo controlled, randomized trial

Cancer microcell initiation and determination

Single nucleotide polymorphisms and the risk of developing a second primary cancer among head and neck cancer patients: a systematic literature review and meta-analysis

Limited recurrence distance of glioblastoma under modern radiotherapy era

Race disparities in mortality by breast cancer from 2000 to 2017 in São Paulo, Brazil: a population-based retrospective study

Response to neoadjuvant chemotherapy based on pathologic complete response in very young patients with ER-positive breast cancer: a large, multicenter, observational study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer